Selenium, Glutathione-peroxidase and Dermatitis herpetiformis

K. LJUNGHALL,¹ L. JUHLIN,¹ L. E. EDQVIST² and L. O. PLANTIN³

¹Department of Dermatology, University Hospital, Uppsala, ²Department of Clinical Chemistry, Veterinary College, Uppsala, and ³Research Center, Huddinge University Hospital, Stockholm

Ljunghall K, Juhlin L, Edqvist LE, Plantin LO. Selenium, glutathione-peroxidase and dermatitis herpetiformis. Acta Derm Venereol (Stockh) 1984; 64: 546-547.

The low levels of glutathione-peroxidase in blood from patients with dermatitis herpetiformis increased after 5 months selenium and vitamin E treatment. In this double-blind study no significant clinical improvement was, however, noted. (Received July 4, 1984).

K. Ljunghall. Department of Dermatology. University Hospital, Uppsala. Sweden.

In patients with dermatitis herpetiformis, decreased blood levels of glutathione-peroxidase (GSH-Px) were common (1). GSH-Px is an index of selenium content and used to detect functional selenium deficiency. We report here the results of a double-blind study where selenium+vitamin E or placebo was added to the dapsone treatment in patients with dermatitis herpetiformis.

PATIENTS

Twenty-four patients (18 men and 6 women, age 32-75 years) were selected for the study. They had all a clinically classical dermatitis herpetiformis and granular deposits of IgA in the papillary tips. During the last year all had needed a constant dose of dapsone (25-200 mg daily) to be free from skin symptoms. For 12-72 months four of them had also used a gluten-free diet without being able to reduce their dapsone intake. Six patients on a normal diet had just started on a gluten-free diet. They were therefore excluded from the study, since it would be difficult to evaluate the clinical effect of selenium supplementation. The patients should be treated double-blind for 5 months twice daily either with placebo or tablets containing 0.2 mg of selenium (as Na₂Se₃)+10 mg tocopheryl succinate.

METHODS

Blood was drawn in 10 ml heparinized vacutainer tubes before treatment and after 2.5 and 5 months. GSH-Px was determined in hemolysed blood as described previously (1, 2). Selenium was in some patients also determined in erythrocytes and plasma by neutron activation analysis (3). The clinical effect of the given tablets was evaluated from the individual dapsone doses needed before and after the trial.

RESULTS

When the study began there was unfortunately a report in press and on television about carcinogenic effects of selenium. Three patients who had read or heard this report stopped

SELENIUM ng/g erythrocytes

the treatment after 2-6 weeks, because they felt worse and had been forced to increase their dapsone intake. They had all received placebo. Out of 15 patients, who completed the study, 10 had received selenium and 5 placebo. No changes in the need for dapsone were noted in either group. No side effects after selenium treatment was noted. The GSH-Px level increased in all patients treated with selenium. The mean \pm SE was 268 \pm 65 µkat/l before and 406 \pm 79 µkat/l after 5 months treatment, which is a significant increase (p<0.001). In the placebo group no significant change was found. The GSH-Px value was correlated to the selenium content in the erythrocytes (Fig. 1). The plasma levels of selenium were 20-30% lower than in the red cells.

DISCUSSION

Since treatment with selenium and vitamin E increased the blood level of GSH-Px without really improving the patients' clinical condition as evaluated from their need for dapsone, the GSH-Px level does not seem to be related to the skin symptoms of the disease itself. The possibility of dapsone influencing the GSH-Px level seems less likely, since there was no correlation with the dose used. It therefore seems most probable that the low GSH-px and selenium levels in blood from patients with dermatitis herpetiformis are due to malabsorption of selenium. Supplementary selenium and vitamin E treatment might therefore still be indicated in such patients for reasons which have not become evident from our study.

REFERENCES

- Juhlin L, Edqvist L-E, Ekman LG, Ljunghall K, Olsson M. Blood glutathione-peroxidase levels in skin diseases: Effect of selenium and vitamin E treatment. Acta Derm Venereol (Stockh) 1982; 62; 211-214.
- 2. Paglia DE, Valentine WN. Studies on the quantitative characterization of erythrocyte glutathione peroxidase. J Lab Clin Med 1967; 70: 158.
- Plantin L-O, Meurling S, Strandvik B. Selenium levels in Swedish children determined with a simple neutron activation analysis method. In: Proceedings of "Mineral Elements ¹80". A Nordic Symposium on soil-plant-animal-man interrelationships and implications to human health, Helsinki 1981; 453-457.



